LGF
VRTX icon

LGT Group Foundation’s Vertex Pharmaceuticals VRTX Stock Holding History

LGT Group Foundation’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Sell
3,769
-71
-2% -$31.5K 0.02% 169
2026
Q1 		$1.71M Sell
3,840
-682
-15% -$318K 0.02% 169
2025
Q4 		$2.05M Sell
4,522
-98
-2% -$42.2K 0.02% 169
2025
Q3 		$1.87M Buy
4,620
+1,881
+69% +$786K 0.02% 173
2025
Q2 		$1.22M Sell
2,739
-649
-19% -$299K 0.02% 193
2025
Q1 		$1.64M Buy
3,388
+1,054
+45% +$491K 0.02% 182
2024
Q4 		$940K Buy
2,334
+129
+6% +$59.8K 0.01% 199
2024
Q3 		$1.02M Buy
+2,205
New +$1.06M 0.02% 210
2023
Q4 		– Sell
-1,246
Closed -$433K – 268
2023
Q3 		$433K Buy
+1,246
New +$436K 0.01% 221

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

LGT Group Foundation's VRTX Position: Q2 2026 in Review

LGT Group Foundation reduced its Vertex Pharmaceuticals (VRTX) stake by 1.8% in Q2 2026, selling an estimated $31.5K and leaving 3,769 shares worth $1.87M. The position accounts for 0.02% of the portfolio, ranked #169.

LGT Group Foundation first reported a position in VRTX in Q3 2023 and has held it in 9 quarters since. The position peaked at $2.05M in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • LGT Group Foundation held 3,769 shares of Vertex Pharmaceuticals worth $1.87M as of Q2 2026.
  • LGT Group Foundation sold 71 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31.5K.
  • Vertex Pharmaceuticals made up 0.02% of LGT Group Foundation's portfolio in Q2 2026, its #169 holding.
  • LGT Group Foundation first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • LGT Group Foundation's Vertex Pharmaceuticals position peaked at $2.05M in Q4 2025.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on LGT Group Foundation's 13F filing for Q2 2026, filed 10 Aug 2026.